Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Part of paid clinical trials in Birmingham, Alabama.

Sponsor: Massachusetts General Hospital
Study ID: NCT05237258
Status: Recruiting

Apply to this trial

Conditions

High Risk Acute Myeloid Leukemia
Primary Refractory Acute Myeloid Leukemia
Relapsed Adult AML

Eligibility Criteria

Sex: ALL
Age: 18 Years - 120 Years
Healthy Volunteers: Accepted

Interventions

Specialty Palliative Care — BEHAVIORAL
Participants assigned to specialty palliative care will be cared for by both oncology and palliative care clinicians during their hospital stays for AML.
Primary Palliative Care — BEHAVIORAL
Participants assigned primary palliative care will be cared for by oncology clinicians who have been trained in palliative care during the hospital stays for AML.

Study Details

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).

Key Dates

Start date: Jun 1, 2022
Status verified: Jul 2025
Primary completion: Apr 30, 2028
Completion: Apr 30, 2029

Study Design

Enrollment: 2,300 participants (estimated)
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Arms

Experimental: Specialty Palliative Care
\- Participants will complete baseline self-report assessments at the time of informed consent
Experimental: Primary Palliative Care
\- Participants will complete baseline self-report assessments at the time of informed consent

Primary Outcome Measure

Quality of Life (QOL) [ Time Frame: Over 12 weeks ]

Central Contacts

Areej El-Jawahri, MD
617-724-4000
[email protected]
Chardria S Trotter, MPH, MBA
[email protected]

Locations (20)

Facility	City	State	ZIP	Site coordinators
University of Alabama - Birmingham	Birmingham	Alabama	35294	Richard Taylor, PhD [email protected] Omer Jamy, MD [email protected]
Stanford University	Stanford	California	94305	Karl Lorenz, MD [email protected] Gabriel Mannis, MD [email protected]
University of Colorado Denver I Anschutz Medical Campus	Denver	Colorado	80204	Stacy Fischer, MD [email protected] Christine McMahon, MD [email protected]
University of Miami	Miami	Florida	33146	Lara Traeger, PhD [email protected] Michael Huber, MD [email protected]
Moffitt Cancer Center	Tampa	Florida	33612	Sara Tinsley-Vance, PhD [email protected] David Craig, PharmD [email protected]
Emory University	Atlanta	Georgia	30322	Dio Kavalieratos, MD [email protected] Martha Arellano, MD [email protected]
Northwestern University	Evanston	Illinois	60208	Jessica Altman, MD [email protected] Jayson Neagle, MD [email protected]
Indiana University	Bloomington	Indiana	47405	Larry Cripe, MD [email protected] James Cleary, MD [email protected]
Johns Hopkins University	Baltimore	Maryland	21218	Corey Tapper, MD [email protected] B. Douglas Smith, MD [email protected]
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Oreofe Odejide, MD, MPH [email protected] James Tulsky, MD [email protected]
Massachusetts General Hospital	Boston	Massachusetts	02115	Areej El-Jawahri, MD [email protected] 617-724-4000 Areej El-Jawahri, MD (PRINCIPAL_INVESTIGATOR) Jennifer Temel, MD (PRINCIPAL_INVESTIGATOR)
Mayo Clinic	Rochester	Minnesota	55905	Jacob Strand, MD [email protected] Hassan Alkhateeb, MD [email protected]
University of Rochester	Rochester	New York	14627	Kah Poh Loh, MD [email protected] Paul Vermilion, MD [email protected]
University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27599	Laura Hanson, MD, MPH [email protected] William Wood, Jr., MD [email protected]
Duke University	Durham	North Carolina	27708	Thomas LeBlanc, MD [email protected] Wil Santivasi, MD [email protected]
Ohio State University	Columbus	Ohio	43210	Erin Stevens, DO [email protected] Alice Mims, MD [email protected]
Oregon Health & Science University	Portland	Oregon	97239	Jason Webb, MD [email protected] Rachel Cook, MD, MS [email protected]
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Selina Luger, MD [email protected] Kathryn McGrath, MD [email protected]
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Mohamed Sorror, MD, MSc [email protected] James Fausto, PhD [email protected]
University of Wisconsin	Madison	Wisconsin	53715	Priyanka Pophali, MD [email protected] Meaghan Trainor, MD [email protected]

Find similar trials in Birmingham, AL

By research site

University of Alabama - Birmingham· Birmingham, AL Stanford University· Stanford, CA University of Colorado Denver I Anschutz Medical Campus· Denver, CO University of Miami· Miami, FL Moffitt Cancer Center· Tampa, FL Emory University· Atlanta, GA

Related Studies

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
PHASE1/PHASE2 · Recruiting · Aptose Biosciences Inc. · Birmingham, Alabama
Novel Digital Application for Patients With Acute Leukemia
Recruiting · Massachusetts General Hospital · Boston, Massachusetts
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
PHASE1/PHASE2 · Recruiting · Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
PHASE1/PHASE2 · Recruiting · Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota